Condition
Gastroesophageal Junction Carcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Gastroesophageal Junction Carcinoma clinical trials that are recruiting, at sites in 9 countries (most in United States (6), China (2), France (1)). By phase: Phase 2 (3), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 9Countries
Newest Gastroesophageal Junction Carcinoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer | Phase 2 | Goodyear, Arizona and 5 other locations | Recruiting | Feb 25, 2026 |
| In-home cancer treatment with remote specialist support for patients in the Florida Panhandle | Phase 2 | Jacksonville, Florida | Recruiting | Dec 16, 2025 |
| Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays | — | Fairbanks, Alaska and 397 other locations | Recruiting | Dec 16, 2025 |
| Evaluating Itraconazole for Treating Esophageal Cancer | Phase 2 | Palo Alto, California and 6 other locations | Recruiting | Oct 3, 2022 |
| Observing cancer recurrence using a blood test | — | Birmingham, Alabama and 56 other locations | Recruiting | Sep 28, 2021 |
| Evaluating TJ033721 for advanced or metastatic solid tumors | Phase 1 | Orange, California and 20 other locations | Recruiting | May 25, 2021 |
All recruiting trials (6)
-
Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer
This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.
-
In-home cancer treatment with remote specialist support for patients in the Florida Panhandle
This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.
-
Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays
This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.
-
Evaluating Itraconazole for Treating Esophageal Cancer
This study is testing if adding the antifungal medication itraconazole to standard treatment can help improve outcomes for patients with operable esophageal cancer.
-
Observing cancer recurrence using a blood test
This study is testing a new blood test to see if it can help find out if cancer comes back in people who have been treated for early-stage solid tumors.
-
Evaluating TJ033721 for advanced or metastatic solid tumors
This study is testing a new drug called TJ033721 to see if it can help people with advanced or metastatic solid tumors, both on its own and in combination with other treatments.
Related topics
Quick answers
How many Gastroesophageal Junction Carcinoma clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 9 countries. The most sites are in United States (6 trials), China (2 trials), France (1 trial), Germany (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.